Related Experiment Videos
Cardiac Natriuretic Peptides, Hypertension and Cardiovascular Risk
Riccardo Sarzani1,2, Francesco Spannella3,4, Federico Giulietti3,4
1Internal Medicine and Geriatrics, Department of Clinical and Molecular Sciences, University "Politecnica delle Marche", Ancona, Italy. r.sarzani@univpm.it.
Insights
Cardiac natriuretic peptides (NPs) are key to cardiovascular health, regulating blood pressure, glucose, and lipid metabolism. Targeting the NP system may reduce hypertension and metabolic-related cardiovascular risks.
Area of Science:
- Cardiovascular Medicine
- Metabolic Syndrome Research
Background:
- Cardiovascular (CV) disease prevalence is rising globally.
- Hypertension, often linked to obesity and metabolic syndrome, is a major CV disease risk factor.
- Understanding mechanisms linking blood pressure, glucose, and lipid dysmetabolism to CV risk is critical.
Purpose of the Study:
- To investigate the role of cardiac natriuretic peptides (NPs) in cardiovascular homeostasis.
- To explore the impact of NPs on blood pressure, glucose, and lipid metabolism.
- To assess the potential of the NP system as a therapeutic target for metabolic-related CV risk.
Main Methods:
- Review of existing literature on cardiac natriuretic peptides (ANP and BNP).
- Analysis of the physiological effects of NPs on blood pressure regulation.
- Examination of NP involvement in glucose and lipid metabolism.
Main Results:
- Cardiac NPs (ANP, BNP) influence blood pressure regulation.
- NPs demonstrate significant effects on glucose and lipid metabolism.
- The collective metabolic and cardiovascular effects of NPs are crucial for reducing overall CV risk.
Conclusions:
- Cardiac NP system plays a vital role in maintaining cardiovascular health and homeostasis.
- NPs impact blood pressure, glucose, and lipid metabolism, suggesting a link between these conditions.
- The cardiac NP system presents a promising therapeutic target for managing hypertension and metabolic-related cardiovascular risks.
Abstract:
Prevalence of cardiovascular (CV) disease is increasing worldwide. One of the most important risk factors for CV disease is hypertension that is very often related to obesity and metabolic syndrome. The search for key mechanisms, linking high blood pressure (BP), glucose and lipid dysmetabolism together with higher CV risk and mortality, is attracting increasing attention. Cardiac natriuretic peptides (NPs), including ANP and BNP, may play a crucial role in maintaining CV homeostasis and cardiac health, given their impact not only on BP regulation, but also on glucose and lipid metabolism. The summa of all metabolic activities of cardiac NPs, together with their CV and sodium balance effects, may be very important in decreasing the overall CV risk. Therefore, in the next future, cardiac NPs system, with its two receptors and a neutralizing enzyme, might represent one of the main targets to treat these multiple related conditions and to reduce hypertension and metabolic-related CV risk.